Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M, Riess H, Sinn BV, Stieler JM, Pelzer U, Striefler JK, Oettle H, Bahra M, Denkert C, Bläker H, Lohneis P. Sinn M, et al. Among authors: lohneis p. Eur J Cancer. 2015 Aug;51(12):1546-54. doi: 10.1016/j.ejca.2015.05.005. Epub 2015 Jun 3. Eur J Cancer. 2015. PMID: 26049689 Clinical Trial.
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C. Sinn M, et al. Among authors: lohneis p. Ann Oncol. 2014 May;25(5):1025-32. doi: 10.1093/annonc/mdu084. Epub 2014 Feb 20. Ann Oncol. 2014. PMID: 24562449 Free article. Clinical Trial.
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, Kakiuchi N, Yoshizato T, Shiozawa Y, Shiraishi Y, Striefler JK, Bischoff S, Lohneis P, Putter H, Blau O, Keilholz U, Bullinger L, Pelzer U, Hummel M, Riess H, Ogawa S, Sinn M, Damm F. Hoyer K, et al. Among authors: lohneis p. EBioMedicine. 2021 Apr;66:103327. doi: 10.1016/j.ebiom.2021.103327. Epub 2021 Apr 13. EBioMedicine. 2021. PMID: 33862582 Free PMC article. Clinical Trial.
Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
Lohneis P, Sinn M, Klein F, Bischoff S, Striefler JK, Wislocka L, Sinn BV, Pelzer U, Oettle H, Riess H, Denkert C, Bläker H, Jühling A. Lohneis P, et al. Br J Cancer. 2018 May;118(11):1485-1491. doi: 10.1038/s41416-018-0093-y. Epub 2018 May 14. Br J Cancer. 2018. PMID: 29755112 Free PMC article.
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial.
Sinn M, Sinn BV, Treue D, Keilholz U, Damm F, Schmuck R, Lohneis P, Klauschen F, Striefler JK, Bahra M, Bläker H, Bischoff S, Pelzer U, Oettle H, Riess H, Budczies J, Denkert C. Sinn M, et al. Among authors: lohneis p. Clin Cancer Res. 2020 Jul 15;26(14):3732-3739. doi: 10.1158/1078-0432.CCR-19-3034. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234756
69 results